The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145)

Folia Histochemica et Cytobiologica

Volumn 46, Issue 2, 2008, Pages 185-191

  Kisielewska, Joanna ^a   Ligeza, Janusz ^a   Klein, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Autocrine growth regulation; DU145 cells; Tyrphostins

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; SU 1498; TRANSFORMING GROWTH FACTOR ALPHA; TYRPHOSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; CINNAMIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MALE; METASTASIS; PROSTATE CANCER; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIUM; DOSE RESPONSE; DRUG EFFECT; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CINNAMATES; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; TYRPHOSTINS;

EID: 48449097555     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0028-1     Document Type: Article

References (47)

1. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 2000;14: 2410-2434.
2. Marker PC, Donjacour AA, Dahiya R, Cunha GR. Hormonal, cellular, and molecular control of prostatic development. Dev Biol. 2003;253:165-174.
3. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem. 2003;253:89-101.
4. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature. 1985;313:745-747.
5. Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res. 1986;46:1015-1029.
6. Bellezza I, Bracarda S, Caserta C, Minelli A. Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgenresponsive prostate cancer in vitro. Mol Genetics Metabolism. 2006;88:114-122.
7. Montano X, Djamgoz MBA. Epidermal growth factor, nerotrophins and the metastatic cascade in prostate cancer. FEBS Lett. 2004;571:1-8.
8. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 1999;54:567-572.
9. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol/Hematol. 2006;58:124-145.
10. Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Nat Cancer Institute. 2001;93:1783-1790.
11. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochem Biophys Acta. 1997;1333:F217-F248.
12. Seth D, Show K, Jazayeri J, Leedman PJ. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-α in human prostate cancer cells. Br J Cancer. 1999;80:657-669.
13. Salomom DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 1995;19:183- 232.
14. Sgambato A, Camerinni A, Faraglia B, et al. Target inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('iressa') induced cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol. 2004; 20: 97- 105.
15. Bonaccorsi L, Marchiani S, Muratori M, Fort Baldi E. Gefitinib ('Iressa, ZD1839) inhibits EGF-induced invasion cancer cells by suppressing PI3K/ AKT activation. J Cancer Res Clin Oncol. 2004;130(10):604-14.
16. Vicetini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by growth factor receptor tyrosine kinase inhibitor ZD1839 in human cell lines and primary cultures. J Cancer Res Clin Oncol. 2003;129:165-174.
17. Blackledge G. Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer theraphy. J Urol. 2003;170:S77-S83.
18. Chan JM, Stampfer MJ, Giovanucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:563-6.
19. Riedemann J, Takiguchi M, Sohail M, Macaulay VM. The EGF receptor interacts with the type 1 IGF receptor and regulates its stability. Biochem Biophys Res Commun. 2007;355: 707-714.
20. Jackson MW, Roberts JS, Heckford SE, et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res. 2002;62:854-859.
21. Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem. 2004;37:618-635.
22. Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol/ Hematol. 2004;50:23-38.
23. Lacal JC. Changing the course of oncogenesis: The development of tyrosine kinase inhibitors. EJC Suppl. 2006;4:14-20.
24. Levitzki A, Gazit A. Tyrosine kinases inhibition: An approach to drug development. Science. 1995;267:1782-1788.
25. Parrizas M, Gaitz A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinol. 1997;138:1427-1433.
26. Strawn LM, McMahon G, App H et al. Flk-1 as a target for growth inhibition. Cancer Res. 1996;56:3540-3545.
27. Boguslawski G, McGlynn PW, Harvey KA, Kovala AT. SU1498, an inhibitor of vascular endothelial growth factor receptor 2, causes accumulation of fosforylated ERK kinases and inhibits their activity in vivo and in vitro. J Biol Chem. 2004;279:5716-5724.
28. Gilles RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem. 1986;159:109-113.
29. Darzynkiewicz Z, Li X, Gong J. Assay of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol. 1994;41:138.
30. Ware J.L. Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metastasis Rev. 1993;12: 287-301.
31. Slater M, Barden JA, Murphy C.R. Changes in growth factor expression in the ageing prostate may disrupt epithelial-stromal homeostasis. Histochem J. 2000;32:357-364.
32. Gowardhan B, West AF, Robson CN, Leung HY. Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells. Prostate. 2004;61:50-59.
33. Walch ET, Marchetti D. Role of neurotropins and neurotropin receptors in the in vitro invasion and heparanase production of human prostate cancer cells. Clin Exp Metastasis. 1999; 17:307-314.
34. Marchiani S, Bonaccorsi L, Ferruzzi P, et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol. 2006;132:408-416.
35. Jones H.E., Goddard L, Gee J.M.W., Hiscox S., Harper M.E., Rubini M., Barrow D., Guy S., Wakeling A., Nicholson R.I. Insulin-like growth factor-1 receptor signaling and acquired resistance to gefitinib (ZD1839, IRESSA) in DU145 human prostate cancer cells. Endocr Relat Cancer. 2004;11:793-814.
36. Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost. 2005;93:964-975.
37. Oki T, Sowa Y, Hirose T, et al. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett. 2004;577:55-59.
38. Turyna B, Jurek A, Gotfryd K, Staśkiewicz A, Kubit P, Klein A. Peritonitis-induced antitumor activity of peritoneal macrophages from uremic patients. Folia Histochem Cytobiol. 2004;42:147-153.
39. Dassonville O, Bozec A, Fischel JL, Milano G. EGFr targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors: Similarities and differences. Crit Rev Oncol/Hematol. 2007;62:53-61.
40. Vicentini C, Festuccia C, Gravina GL, Adriano A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol. 2003;129: 165-174.
41. Rabindran S.K. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005;227:9-23.
42. Jimeno A, Hidalgo M. Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol/Hematol. 2005;53: 179-192.
43. Kimura G, Kasuya J,Giannini S, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines. Int J Urol. 1996;3:39-46.
44. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003;63:5073-5083.
45. Meinbach DS, Lokeshwar BMD. Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence? Urol Oncol Seminars Orginal Invest. 2006;24:294-306.
46. Figuerola JA, Lee AV, Jackson JG, Yee D. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrionol Metab. 1995;80:3476-3482.
47. Pu YS, Hsieh MW, Wang CW et al. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol. 2006;71:751-760.